The current PE ratio of IRWD can't be determined, as the TTM EPS of -$6.45 is negative. Ironwood Pharmaceuticals's last PE ratio on record was 8.92 in March 2023.
The mean historical PE ratio of Ironwood Pharmaceuticals over the last five years is 16.3. Over the past five years, IRWD's PE ratio was at its highest in the Dec 2019 quarter at 95.07, with a price of $13.31 and an EPS of $0.14. The Dec 2021 quarter recorded the bottom point at 3.58, with a price of $11.66 and an EPS of $3.26.
Maximum annual increase: 206.15% in 2022
Maximum annual decrease: -82.12% in 2020
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | 10.96 | 206.15% |
| 2021 | 3.58 | -78.94% |
| 2020 | 17 | -82.12% |
| 2019 | 95.07 | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
| Stock name | PE ratio | Market cap |
|---|---|---|
| AZN Astrazeneca plc | 37.24 | $236.71B |
| NKTR Nektar Therapeutics | N/A | $288.28M |
| CPIX Cumberland Pharmaceuticals Inc | N/A | $22.4M |
| IRWD Ironwood Pharmaceuticals Inc | N/A | $1.27B |
The current price to earnings ratio of IRWD can't be calculated, as its EPS of -$6.45 is negative.
Over the last 3 years, the average price to earnings ratio for IRWD stock is 6.97.
Over the last 5 years, the average price to earnings ratio for IRWD stock is 16.3.
In the last five years, the Dec 2019 quarter recorded the highest quarterly PE ratio at 95.07.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.